Fibroblast growth factor receptor 3 and the human chondrodysplasias

Current Opinion in Pediatrics

Volumn 9, Issue 4, 1997, Pages 437-442

  Horton, William A ^a  

^a SHRINERS HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ACHONDROPLASIA; BONE GROWTH; CHONDRODYSPLASIA PUNCTATA; DIMERIZATION; DISEASE SEVERITY; ENZYME ACTIVITY; GENE MUTATION; GROWTH PLATE; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; THANATOPHORIC DWARFISM;

EID: 0030773251     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199708000-00021     Document Type: Short Survey

References (49)

1. Velinov M, Slaugenhaupt SA, Stoilov I, Scott CI, Gusella JF, Tsipouris P: The gene for achondroplasia maps to the telomeric region of chromosome 4p. Nat Genet 1994, 5:314-317.
2. Le Merrer M, Rousseau F, Legeai-Mallet L, Landais J-C, Pelet A, Bonaventure J, Sanak M, Weissenbach J, Stoll C, Munnich A, et al.: A gene for achondroplasia-hypochondroplasia maps to chromosome 4p. Nat Genet 1994, 6:318-321.
3. Francomano CA, de Luna RIO, Hefferson TW, Bellus GA, Turner CE, Taylor E, Meyers DA, Blanton SH, Murray JC, McIntosh I, et al.: Localization of the achondroplasia gene to the distal 2.5 Mb of human chromosome 4p. Hum Mol Genet 1994, 3:787-792.
4. Shiang R, Thompson LM, Zhu Y-Z, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ: Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994, 78:335-342.
5. Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet J, Maroteaux P, Le Merrer M, Munnich A: Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1995, 371:252-254.
6. Bellus G, Hefferon T, Ortiz de Luna R, Hecht J, Horton W, Machado M, Kaitila I, McIntosh I, Francomano C: Achondroplasia is defined by recurrent G380R mutations In FGFR3. Am J Hum Genet 1995, 56:368-373. This paper addresses the high mutability of the human FGFR3 gene relative to other human genes.
7. Superti-Furga A, Eich GU, Bucher H, Widder J, Giedion A, Gitzelmann R, Steinmann B: A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur J Pediatr 1995, 95:215-219.
8. Tavormina P, Shiang R, Thompson L, Zhu Y, Wilkin D, Lachman R, Wilcox W, Rimoin D, Cohn D, Wasmuth J: Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 1995, 9:321-328.
9. Rousseau F, Saugier P, Le Merrer M, Munnich A, Delezoide A, Maroteaux P, Bonaventure J, Narcy F, Sanak M: Stop codon FGFR3 mutations in thanatophoric dysplasia type I. Nat Genet 1995, 10:11-12.
10. Bellus GA, McIntosh I, Smith EA, Aylsworth AS, Kaitila I, Horton WA, Greenhaw GA, Hecht JT, Francomano CA: A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995, 10:357-359.
11. Prinos P, Costa T, Sommer A, Kilpatrick MW, Tsipouras P: A common FGFR3 gene mutation in hypochondroplasia. Hum Mol Genet 1995, 4:2097-2101.
12. Tonoki H, Nakae J, Tajima T, Shinohara N, Monji J, Satoh S, Fujieda K: Predominance of the mutation at 1138 of the cDNA for the fibroblast growth factor receptor 3 in Japanese patients with achondroplasia. Jpn J Hum Genet 1995, 40:347-349.
13. Alderbom A, Anvret M, Gustavson KH, Hagenas L, Wadelius C: Achondroplasia in Sweden caused by the G1138A mutation in FGFR3. Acta Paediatr 1996, 85:1506-1507.
14. Pokharel RK, Alimsardjono H, Takeshima Y, Nakamura H, Naritomi K, Hirose S, Onishi S, Matsuo M: Japanese cases of type 1 thanatophoric dysplasia exclusively carry a C to T transition at nucleotide 742 of the fibroblast growth factor receptor 3 gene. Biochem Biophys Res Commun 1996, 227:236-239.
15. Wang TR, Wang WP, Hwu WL, Lee ML: Fibroblast growth factor receptor 3 (FGFR3) gene G1138A mutation in Chinese patients with achondroplasia. Hum Mutat 1996, 8:178-179.
16. Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Maroteaux P, Le Merrer M, Munnich A: Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia. Horm Res 1996, 45:108-110.
17. Rousseau F, Bonaventure J, Le Merrer M, Munnich A: Association of achondroplasia to a mutation in the transmembrane domain of fibroblastic growth factor receptor 3 (FGFR3). Ann Endocrinol 1996, 57:151-152.
18. Rousseau F, Bonaventure J, Le Merrer M, Maroteaux P, Munnich A: Mutations of FGFR3 gene cause 3 types of nanisms with variable severity: achondroplasia, thanatophoric nanism and hypochondroplasia. Ann Endocrinol 1996, 57:153.
19. Rousseau F, Bonaventure J, Legeai-Mallet L, Schmidt H, Weissenbach J, Maroteaux P, Munnich A, Le Merrer M: Clinical and genetic heterogeneity of hypochondroplasia. J Med Genet 1996, 33:749-752.
20. Rousseau F, El Ghouzzi V, Delezoide AL, Legeai-Mallet L, Le Merrer M, Munnich A, Bonaventure J: Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet 1996, 5:509-512.
21. Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW: Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 1995, 11:462-464.
22. Wilkes D, Rutland P, Pulleyn LJ, Reardon W, Moss C, Ellis JP, Winter RM, Malcolm S: A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans. J Med Genet 1996, 33:744-748.
23. Bellus GA, Gaudenz K, Zackai EH, Clarke LA, Szabo J, Francomano CA, Muenke M: Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nat Genet 1996, 14:174-176.
24. Muenke M, Gripp KW, McDonald-McGinn D, Gaudenz K, Whitaker LA, Bartlett SP, Markowitz RI, Robin NH, Nwokoro N, Mulvihill JJ, et al.: A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am J Hum Genet 1997, 60:555-564. This article delineates the clinical features of a new craniosynostosis syndrome that is especially interesting because all patients have the same mutation that maps very close to one of the TDI mutation sites in FGFR3.
25. Basilico C, Moscatelli D: The FGF family of growth factors and oncogenes. Adv Cancer Res 1992, 59:115-165.
26. van der Geer P, Hunter T, Lindberg RA: Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994, 10:251-337.
27. Wuechner C, Nordqvist AC, Winterpacht A, Zabel B, Schalling M: Developmental expression of splicing variants of fibroblast growth factor receptor 3 (FGFR3) in mouse. Int J Dev Biol 1996, 40:1185-1188.
28. Smallwood PM, Munoz-Sanjuan I, Tong P, Macke JP, Hendry SHC, Gilbert DJ, Copeland NG, Jenkins NA, Nathans J: Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proc Natl Acad Sci U S A 1996, 93:9850-9857.
29. Chellaiah AT, McEwen DG, Werner S, Xu J, Ornitz DM: Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J Biol Chem 1994, 269:11620-11627.
30. Hecht D, Zimmerman N, Bedford M, Aviva A, Yayon A: Identification of fibroblast growth factor 9 (FGF9) as a high affinity, heparin dependent ligand for FGR receptors 3 and 2 but not for FGF receptors 1 and 4. Growth Factors 1995, 12:223-233.
31. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996, 271:15292-15297.
32. Santos-Ocampo S, Colvin JS, Chellaiah A, Ornitz DM: Expression and biological activity of mouse fibroblast growth factor-9. J Biol Chem 1996, 271:1726-1731.
33. Kanai M, Göke M, Tsunekawa S, Podolsky DK: Signal transduction pathway of human fibroblast growth factor receptor 3. J Biol Chem 1997, 272:6621-6628. This paper elucidates how FGFR3 activates the MAP kinase mitogenic pathway. It addresses the molecular interactions that are involved in transmitting signals from activated FGFR3 to ras and downstream through the MAP kinase pathway.
34. Schlessinger J, Lax I, Lemmon M: Regulation of growth factor activation by proteoglycans: what is the role of low affinity receptors? Cell 1995, 83:357-360.
35. Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, Schlessinger J: Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 1996, 97:977-989.
36. Mohammadi M, Schlessinger J, Hubbard SR: Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell 1996, 86:577-587.
37. Klint P, Kanda S, Claesson-Welsh L: Shc and a novel 89-kDa component couple to the Grb2-Sos complex in fibroblast growth factor-2 stimulated cells. J Biol Chem 1995, 270:23337-23344.
38. Su, W-CS, Kitagawa M, Xue N, Xie B, Garofalo S, Cho J, Deng C, Horton WA, Fu X-Y: Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 1997, 386:288-291. This paper establishes the link between activated FGFR3 through STAT1 to p21, which serves as an antimitotic influence on growth plate chondrocytes. It demonstrates activation of STAT1 and enhanced expression of p21 in the growth plate of infants with TDII.
39. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P: Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996, 84:911-921.
40. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM: Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 1996, 12:390-397.
41. Spranger J, Maroteaux P: The lethal osteochondrodysplasia. Adv Hum Genet 1995, 19:1-103.
42. Wilkie A, Moriss-Kay G, Jones E, Heath J: Functions of fibroblast growth factors and their receptors. Curr Biol 1995, 5:500-507.
43. Webster MK, Donoghue DJ: Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 1996, 15:520-527. This paper describes chimeric receptor experiments showing that achondroplasia (transmembrane) mutation alone can activate a transmembrane receptor, probably by promoting ligand-independent dimerization. It offers a mechanism to explain how the achondroplasia mutation constitutively activates FGFR3.
44. Sorokin A, Lemmon MA, Ullrich A, Schlessinger J: Stabilization of an active dimeric form of the epidermal growth factor receptor by introduction of an Inter-receptor disulfide bond. J Biol Chem 1994, 269:9752-9759.
45. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, et al.: Activation of RET as a dominant transforming gene by germ-line mutations of MEN 2A and MEN 2B. Science 1995, 267:381-383.
46. Webster MK, d'Avis PY, Robertson SC, Donoghue DJ: Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 1996, 16:4081-4087. This article examines the molecular nature of the TDII mutation and demonstrates how the mutation activates kinase activity of FGFR3 independent of ligand.
47. Sorokin A, Mahammadi M, Huang J, Schlessinger J: Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766. J Biol Chem 1994, 269:17056-17061.
48. Naski MC, Wang Q, Xu J, Ornitz DM: Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 1996, 13:233-237.
49. Horton WA: Molecular genetic basis of the human chondrodysplasias. Endocrinol Metab Clin NA 1996, 25:683-697.